Combination therapy in multiple sclerosis

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

1998 • 9,382 citations

Axonal Transection in the Lesions of Multiple Sclerosis

1998 • 4,007 citations

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

2004 • 2,504 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

TNF neutralization in MS

1999 • 968 citations

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

2002 • 937 citations

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

2001 • 697 citations

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

2001 • 595 citations

Effect of relapses on development of residual deficit in multiple sclerosis

2003 • 412 citations

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

1998 • 367 citations

Cladribine and progressive MS

2000 • 317 citations

Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

1995 • 309 citations

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy

2002 • 268 citations

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis

1991 • 248 citations

Differential mechanisms of action of interferon-β and glatiramer acetate in MS

2002 • 238 citations

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

1999 • 232 citations

Overview of azathioprine treatment in multiple sclerosis

1991 • 222 citations

Risk of cancer from azathioprine therapy in multiple sclerosis

1996 • 203 citations

Linomide in relapsing and secondary progressive MS

2000 • 171 citations

The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis

1998 • 94 citations

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality

2003 • 86 citations

Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein

1995 • 50 citations

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.

1991 • 48 citations

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-?) does not improve experimental autoimmune encephalomyelitis

2000 • 47 citations

Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis

2005 • 40 citations

Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

2002 • 23 citations

IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS

2004 • 3 citations